<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578772</url>
  </required_header>
  <id_info>
    <org_study_id>miFMD</org_study_id>
    <nct_id>NCT01578772</nct_id>
  </id_info>
  <brief_title>A Clinical Trial for People HIV+ Age &gt; 50 at Risk for Heart Disease</brief_title>
  <official_title>Telmisartan and Flow-Mediated Dilatation in Older HIV-Infected Patients at Risk for Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Campbell Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is to see whether blood vessel function, an early sign of heart disease,
      improves in HIV-infected men and women who take telmisartan for 12 weeks. The investigators
      will be looking at how a blood vessel in the arm, called the brachial artery, changes in
      response to stress before and after taking telmisartan. To determine how well the blood
      vessel functions, the investigators will be using an ultrasound machine.

      Telmisartan is not an HIV medication. It is an FDA-approved medication designed to treat
      blood pressure, but has been shown to improve blood vessel function in HIV-negative people
      with and without high blood pressure. Telmisartan is made by Boehringer Ingelheim, and this
      trial is sponsored by The Campbell Foundation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-week Change in Diameter and Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy</measure>
    <time_frame>6 weeks (after baseline)</time_frame>
    <description>Flow-mediated dilatation (FMD) testing of the brachial artery was performed for all participants on Telmisartan treatment at baseline and 6 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6-week Change in Maximum Relative Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy</measure>
    <time_frame>6 weeks (after baseline)</time_frame>
    <description>Flow-mediated dilatation (FMD) testing of the brachial artery was performed for all participants on Telmisartan treatment at baseline and 6 weeks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>80mg tablets po daily for 6 weeks</description>
    <arm_group_label>Telmisartan</arm_group_label>
    <other_name>Micardis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive men and women &gt; 50 years of age.

          -  HIV-1 RNA documented to be &lt; 50 copies/mL at screening and undetectable by assay of
             choice (&lt; 50 or &lt; 400 copies/mL) for at least 12 weeks prior to entry.

          -  Current ART with a suppressive, highly active regimen. Subjects must not have changed
             ART in the 12 weeks prior to entry, and must not be planning to change ART for the
             12-week study duration.

          -  Systolic blood pressure &gt; 110mmHg.

          -  One or more risk factors for CVD (smoking, hypertension, hyperlipidemia, diabetes
             mellitus). Note: family history of early heart disease alone will not be a sufficient
             entry criterion.

          -  Ability and willingness of subject to provide informed consent.

        Exclusion Criteria:

          -  Pregnancy (current or within the past 6 months) or nursing.

          -  Uncontrolled hypertension:

          -  Prohibited concomitant medications: Other members of the angiotensin receptor-blocking
             class (losartan, irbesartan, olmesartan, valsartan, candesartan; wash-out period
             allowed), nelfinavir, and etravirine. Subjects taking nelfinavir or etravirine will be
             excluded due to the possibility of increased drug levels via inhibition of cytochrome
             P-450 2C19.

        Note 1: Subjects requiring amifostine or rituximab must be aware of the increased risk of
        orthostatic hypotension with the addition of telmisartan. Any subject requiring lithium
        therapy while on study must have lithium levels monitored closely by their outside
        physician. All subjects on the above listed medications should provide documentation that
        their physician is aware of the study protocol.

        Note 2: Subjects taking thiazolidinediones must be on stable dosing (&gt; 12 weeks) and must
        agree to refrain from dose titration for the 12-week study duration.

          -  Untreated hyperlipidemia: Subjects must be willing to abstain from initiating therapy
             for the 12-week study duration. Subjects on a stable (&gt; 12 weeks) lipid-lowering
             regimen must be willing to remain on their current dose for the 12-week study
             duration.

          -  Subjects undergoing treatment for diabetes with oral hypoglycemic agents must be
             willing to remain on their current dose of insulin-sensitizing agents
             (metformin/biguanides) for the 12-week study duration. Titration of other diabetes
             (except thiazolidinediones, see 4.2.3) medications will be permitted.

          -  Screening laboratory values as follows:

          -  ANC &lt; 750 cells/mm3

          -  Hemoglobin &lt; 10 gm/dL

          -  Creatinine clearance &lt; 30 mL/min (estimated by Cockcroft-Gault equation using ideal
             body weight)

          -  AST or ALT &gt; 3 times ULN

          -  Known, untreated, renal artery stenosis.

          -  Unstable coronary artery disease/angina, decompensated congestive heart failure, or
             predicted need for cardiovascular surgery within the study period.

          -  History of intolerance to any member of the angiotensin receptor blocker class of
             agents.

          -  Need for ongoing potassium supplementation.

          -  Active, untreated opportunistic and/or AIDS-defining illnesses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan E. Lake, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>April 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <results_first_submitted>September 4, 2014</results_first_submitted>
  <results_first_submitted_qc>December 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2014</results_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Jordan E. Lake M.D.</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Flow-mediated dialation (FMD)</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>Cardiovascular disease (CVD)</keyword>
  <keyword>HIV+ men and women age &gt; 50 at risk for heart disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan</title>
          <description>Open label
Telmisartan: 80mg tablets po daily for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>HIV-infected individual &gt;50 years old with HIV-1 RNA &lt;50 copies /mL on stable ART and &gt;=1 CVD risk factor.</population>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan</title>
          <description>Open label
Telmisartan: 80mg tablets po daily for 6 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="54" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>6-week Change in Diameter and Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy</title>
        <description>Flow-mediated dilatation (FMD) testing of the brachial artery was performed for all participants on Telmisartan treatment at baseline and 6 weeks.</description>
        <time_frame>6 weeks (after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline (Week 0)</title>
            <description>All participants received telmisartan 80mg tablets po daily for 6 weeks. Flow-mediated dilatation (FMD) testing was performed for all participants at baseline (week 0) and 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Week 6</title>
            <description>All participants received telmisartan 80mg tablets po daily for 6 weeks. Flow-mediated dilatation (FMD) testing was performed for all participants at baseline (week 0) and 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>6-week Change in Diameter and Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy</title>
          <description>Flow-mediated dilatation (FMD) testing of the brachial artery was performed for all participants on Telmisartan treatment at baseline and 6 weeks.</description>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Brachial Artery Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="4.4" upper_limit="4.9"/>
                    <measurement group_id="O2" value="4.7" lower_limit="4.4" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum Absolute FMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.1" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.1" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Pairwise comparisons were performed using Wilcoxon signed rank test. All statistical tests are two-sided with nominal alpha level of 0.05.</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>6-week Change in Maximum Relative Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy</title>
        <description>Flow-mediated dilatation (FMD) testing of the brachial artery was performed for all participants on Telmisartan treatment at baseline and 6 weeks.</description>
        <time_frame>6 weeks (after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline (Week 0)</title>
            <description>All participants received telmisartan 80mg tablets po daily for 6 weeks. Flow-mediated dilatation (FMD) testing was performed for all participants at baseline (week 0) and 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Week 6</title>
            <description>All participants received telmisartan 80mg tablets po daily for 6 weeks. Flow-mediated dilatation (FMD) testing was performed for all participants at baseline (week 0) and 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>6-week Change in Maximum Relative Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy</title>
          <description>Flow-mediated dilatation (FMD) testing of the brachial artery was performed for all participants on Telmisartan treatment at baseline and 6 weeks.</description>
          <units>percentage of maximum relative FMD</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.4" upper_limit="3.9"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.6" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Pairwise comparisons were performed using Wilcoxon signed rank test. All statistical tests are two-sided with nominal alpha level of 0.05.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks (after baseline)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan</title>
          <description>Open label
Telmisartan: 80mg tablets po daily for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Given the limited size of the study population, the study was underpowered.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jordan Lake</name_or_title>
      <organization>UCLA</organization>
      <phone>310-557-2273</phone>
      <email>jlake@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

